Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;10(2):73-80.
doi: 10.1016/j.clcc.2011.03.001. Epub 2011 Apr 22.

Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?

Affiliations
Review

Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?

Robin K Kelley et al. Clin Colorectal Cancer. 2011 Jun.

Abstract

Conventional clinical and pathologic risk factors in stage II colon cancer provide limited prognostic information and do not predict response to adjuvant 5-fluorouracil-based chemotherapy. New prognostic and predictive biomarkers are needed to identify patients with highest recurrence risk who will receive the greatest absolute risk reduction from adjuvant chemotherapy. We review below the evidence for conventional risk factors in patients with node-negative colon cancer, followed by a discussion of promising new molecular and genetic markers in this malignancy. Gene expression profiling is an emerging tool with both prognostic and predictive potential in oncology. For patients with stage II colon cancer, the Oncotype DX Colon Cancer test is now commercially available as a prognostic marker, and the ColoPrint assay is expected to be released later this year. Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ECOG 5202 Study Schema (Is permission needed? This is from the ECOG flyer for the trial.)

Similar articles

Cited by

References

    1. Horner MJRL, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; 2009. FS2.
    1. Cancer in California . Department of Health Services; State of California: Dec, 2005. 1988-2002. 2005.[FS3]
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
    1. Quasar Collaborative G. Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9. [FS4][FS5] - PubMed
    1. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94. - PubMed

Publication types

Substances